Allergenic products advisory committee
Executive Summary
FDA's Allergenic Products Advisory Committee will address reclassification of Class IIIA allergenic products at an April 7 meeting. Under the classification system for biologics approved prior to 1972, Class III included products that do not have sufficient data for classification; the agency is eliminating the IIIA category, which allowed products to remain on the market until data is collected. An update on FDA's "critical path" initiative is also scheduled. The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 8:30 a.m...